目的探讨托吡酯治疗中出现泌汗障碍的临床特点及相关危险因素。方法回顾全国托吡酯上市后疗效和安全性监测多中心观察的10106例癫痫患者的临床资料,分析泌汗障碍的发生率、临床特点及危险因素。结果378例(3.74%)发生泌汗障碍,儿童发生率(5.50%)显著高于成人(0.37%)(P<0.05)。性别、发作频率、是否加用其他抗癫痫药物及疗效并不影响泌汗障碍的发生,而低龄、剂量较高者在夏季较易出现此种不良反应。儿童患者各年龄组内,泌汗障碍患者与未发生泌汗障碍者的平均剂量均无明显差异。结论泌汗障碍在托吡酯治疗的儿童患者中较为常见,应积极预防并予以相应处理。夏季和低龄是发生泌汗障碍的危险因素,而剂量并不是发生泌汗障碍的主要影响因素。 Objective To investigate the clinical features and related risk factors of hyperuricemia in topiramate treatment. Methods To review the clinical data of 10,106 epilepsy patients who were treated with Topiramate on the market and safety monitoring after multinational surveillance. The incidence, clinical features and risk factors of dysuria were analyzed. Results 378 cases (3.74%) had dysuria, and the incidence of children (5.50%) was significantly higher than that of adults (0.37%) (P <0.05). Gender, frequency of seizures, whether to add other anti-epileptic drugs and efficacy does not affect the occurrence of dysuria, while younger, higher doses in the summer is more prone to such adverse reactions. Children in all age groups, patients with dysuria and those without hysteropathy had no significant difference in the average dose. Conclusions Perspiration disorder is more common in children treated with topiramate and should be actively managed and treated accordingly. Summer and early age are the risk factors of dysuria, and dose is not the main influencing factor of dysuria.